Johnson & Johnson Innovation – JJDC returned for Cue Health’s $100m series C round as the medical diagnostics system developer seeks regulatory approval for its Covid-19 test.
US-based molecular testing technology developer Cue Health completed a $100m series C round yesterday backed by healthcare group Johnson & Johnson’s corporate venturing subsidiary, Johnson & Johnson Innovation – JJDC.
Decheng Capital, Foresite Capital, Madrone Capital Partners, Acme Capital and undisclosed investment firms also contributed to the round, which took the total raised by the company to more than $169m.
Founded in 2010, Cue develops medical diagnostic devices for use by consumers at home and by professionals in clinical settings.…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
